{"id":925416,"date":"2026-01-08T10:01:19","date_gmt":"2026-01-08T15:01:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/"},"modified":"2026-01-08T10:01:19","modified_gmt":"2026-01-08T15:01:19","slug":"alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/","title":{"rendered":"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <strong><br \/>\n          <em>&#8211; First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician\u2019s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 \u2013<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"center\">\n        <strong><br \/>\n          <em>&#8211; Third dose cohort initiated in Phase 1 trial of ALX 2004; study remains on track to provide <\/em><br \/>\n        <\/strong><br \/>\n        <strong><br \/>\n          <em>initial safety data in 1H 2026 &#8211;<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>SOUTH SAN FRANCISCO, Calif., Jan.  08, 2026  (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology,\u201d Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, announced that the first patient has been dosed in the Company\u2019s Phase 2 ASPEN-09-Breast trial evaluating its investigational CD47-inhibitor evorpacept. This trial will evaluate the combination of evorpacept with trastuzumab and physicians\u2019 choice of chemotherapy in patients with HER2-positive metastatic breast cancer whose disease has progressed after ENHERTU<sup>\u00ae<\/sup> (T-DXd).<\/p>\n<p>Additionally, after successfully clearing the second dose cohort, the Phase 1 trial evaluating the Company\u2019s epidermal growth factor receptor (EGFR)-targeted antibody-drug conjugate (ADC) ALX2004 for the treatment of EGFR-expressing solid tumors has begun enrolling patients in the third dose cohort at 4mg\/kg. No dose-limiting toxicities were observed in the prior two dose cohorts.<\/p>\n<p>\u201cWe are extremely pleased with the progress we are making on these clinical trials,\u201d said Jason Lettmann, Chief Executive Officer at ALX Oncology. \u201cWe believe both evorpacept and ALX2004 have the potential to fill significant gaps in the standard of care for many types of cancer.\u201d<\/p>\n<p>Evorpacept is the first CD47 inhibitor to show substantial tumor response and a well-tolerated safety profile in a randomized trial. Data from this prior gastric cancer trial, ASPEN-06, show that evorpacept demonstrated benefit across all efficacy parameters in patients with HER2-positive disease and high CD47 expression levels. Research has demonstrated that increased CD47 expression is correlated with poor patient outcomes in many tumor types, including breast cancer.<\/p>\n<p>The Phase 2 ASPEN-09-Breast clinical trial (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rcAzAw0lE_KYUdTR4R_aAwJiMtk8x253WiW2ZyKRGRBS7KByxrZWs4uCqvMedudvIjQjF1ufAOW76_LNddmCQ0mZYGsdtz9ACyURqJA12N9Txz6qJE_3jfyCoDBbwwoM3OkKzb2VWPuh4l06FIfWgvYNlVIgLer5HvMsVDpmEX0=\" rel=\"nofollow\" target=\"_blank\">NCT07007559<\/a>) is a single-arm, open-label, multicenter study evaluating evorpacept plus trastuzumab and physicians\u2019 choice of chemotherapy in 80 patients with HER2-positive breast cancer previously treated with ENHERTU<sup>\u00ae<\/sup>\u00a0(fam-trastuzumab deruxtecan-nxki), which was recently approved as first-line therapy. The trial will utilize participants\u2019 CD47 expression levels as a biomarker to assess responses.<\/p>\n<p>The primary endpoint of the trial is overall response rate (ORR) in patients who are confirmed HER2 positive by circulating tumor DNA (ctDNA). Key secondary endpoints are ORR in the HER2 ctDNA+ subpopulation by level of CD47 expression, clinical benefit rate (CBR), duration of response (DOR), progression-free survival (PFS) and overall survival (OS), and safety. ORR in the HER2 ctDNA-negative subpopulation is an exploratory endpoint. ALX Oncology anticipates sharing interim data from the trial in Q3 2026.<\/p>\n<p>The ALX2004 Phase 1 clinical trial (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rcAzAw0lE_KYUdTR4R_aA8Lf7F-D0h0KA2BkDNOpl2VuV1Q5VoUgPO8u_CFZU5WoVCOpugQ7ANvlhy-GmjysAblehd2jsmeen6F1Sb93hr_CEL8IUrYFgZSew71rzlHYHdcvTp3Ib9hL1Cx6Jw_ImcCIB2kKvQO4lA6GREXXezSlutos_hivrTegpc46Fp5r0NrdAIkFx7hnltUA-kDGsoMLgU3mOlV-qEuyPB4vuVva1GwVL7tkyEWAkr8tHumTZgGtEmKFOBgTtxSUgoLcdBc_eSsbx-Fj1DkFpfTIvFhlEjb2KeK1-xzvjde6hgYD\" rel=\"nofollow\" target=\"_blank\">NCT07085091<\/a>) is a first-in-human, open-label, multicenter trial evaluating ALX2004 in participants with advanced or metastatic select EGFR-expressing solid tumors. The study consists of a Phase 1a dose escalation portion followed by optional dose exploration, and a Phase 1b dose expansion. The dose escalation portion of the trial is enrolling patients with previously treated advanced or metastatic non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), esophageal squamous cell carcinoma (ESCC) and colorectal cancer (CRC).<\/p>\n<p>\u201cPreclinical data suggest that ALX2004 has the potential to overcome the toxicity challenges associated with earlier generation EGFR-targeted ADCs,\u201d said Lettmann. \u201cIt is encouraging that, after clearing the second dose cohort in our Phase 1 trial at 2mg\/kg, we are able to double the dosage to 4mg\/kg in the third cohort.\u201d<\/p>\n<p>ALX Oncology expects to provide an initial safety update from the Phase 1 ALX2004 trial during 1H 2026.<\/p>\n<p>\n        <strong>About ALX Oncology<\/strong><br \/>\n        <br \/>ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives. ALX Oncology\u2019s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology\u2019s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors.<\/p>\n<p>\n        <strong>Cautionary Note Regarding Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements regarding future results of operations and financial position, business strategy, product candidates, planned preclinical studies and clinical trials, results of clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, plans and objects of management for future operations, as well as statements regarding industry trends. Such forward-looking statements are based on ALX Oncology\u2019s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause ALX Oncology\u2019s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in ALX Oncology\u2019s filings with the Securities and Exchange Commission (SEC), including ALX Oncology\u2019s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and other documents ALX Oncology files with the SEC from time to time. Except to the extent required by law, ALX Oncology undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.<\/p>\n<p>More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xt9DQaO770pmtuTfxGg6JWqr7RnSkiAA3THzwxmx5ADbykgadZrVejpazry2HwPNZianAHxzhX5o9aXfuyb7CMFAOTtzSqVaF7ZctjhECD8=\" rel=\"nofollow\" target=\"_blank\"><u>www.alxoncology.com<\/u><\/a> and on LinkedIn @<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cYOBhv47W7Kjk0I8MruuJBpx-72OBDbo6EZzVUAuzqGbAQgUn9ssIoH6o1M3isPASVCMP0KLsEG-gQBd9ME4K5JQUBPkNoEqCKevqg8xnYI87aG_xfOPyFsa4Ff2a-0U\" rel=\"nofollow\" target=\"_blank\"><u>ALX Oncology<\/u><\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact: <\/strong><br \/>\n        <br \/>Elhan Webb, CFA, IR Consultant<br \/>ewebb@alxoncology.com<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Michele Parisi, SparkPoint Healthcare Communications<br \/>mparisi@sparkpointpr.com<br \/>(925) 864-5028<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjA4MSM3MzUwNTQ5IzIxOTI4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZTc2M2ExMmQtNGQ3Yi00YjQzLTgxN2QtZGQ4Mzc1NjZlZTNkLTEyMDQ0MTYtMjAyNi0wMS0wOC1lbg==\/tiny\/ALX-Oncology.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician\u2019s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 \u2013 &#8211; Third dose cohort initiated in Phase 1 trial of ALX 2004; study remains on track to provide initial safety data in 1H 2026 &#8211; SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology,\u201d Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, announced that the first patient has been dosed in the Company\u2019s Phase 2 ASPEN-09-Breast trial evaluating its investigational CD47-inhibitor evorpacept. This trial will evaluate the combination of evorpacept &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-925416","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician\u2019s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 \u2013 &#8211; Third dose cohort initiated in Phase 1 trial of ALX 2004; study remains on track to provide initial safety data in 1H 2026 &#8211; SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology,\u201d Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, announced that the first patient has been dosed in the Company\u2019s Phase 2 ASPEN-09-Breast trial evaluating its investigational CD47-inhibitor evorpacept. This trial will evaluate the combination of evorpacept &hellip; Continue reading &quot;ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T15:01:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjA4MSM3MzUwNTQ5IzIxOTI4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004\",\"datePublished\":\"2026-01-08T15:01:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/\"},\"wordCount\":952,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjA4MSM3MzUwNTQ5IzIxOTI4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/\",\"name\":\"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjA4MSM3MzUwNTQ5IzIxOTI4NjM=\",\"datePublished\":\"2026-01-08T15:01:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjA4MSM3MzUwNTQ5IzIxOTI4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTYyMjA4MSM3MzUwNTQ5IzIxOTI4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/","og_locale":"en_US","og_type":"article","og_title":"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - Market Newsdesk","og_description":"&#8211; First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician\u2019s choice of chemotherapy in HER2-positive metastatic breast cancer; interim analysis anticipated Q3 2026 \u2013 &#8211; Third dose cohort initiated in Phase 1 trial of ALX 2004; study remains on track to provide initial safety data in 1H 2026 &#8211; SOUTH SAN FRANCISCO, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc. (\u201cALX Oncology,\u201d Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, announced that the first patient has been dosed in the Company\u2019s Phase 2 ASPEN-09-Breast trial evaluating its investigational CD47-inhibitor evorpacept. This trial will evaluate the combination of evorpacept &hellip; Continue reading \"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/","og_site_name":"Market Newsdesk","article_published_time":"2026-01-08T15:01:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjA4MSM3MzUwNTQ5IzIxOTI4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004","datePublished":"2026-01-08T15:01:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/"},"wordCount":952,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjA4MSM3MzUwNTQ5IzIxOTI4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/","name":"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjA4MSM3MzUwNTQ5IzIxOTI4NjM=","datePublished":"2026-01-08T15:01:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjA4MSM3MzUwNTQ5IzIxOTI4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyMjA4MSM3MzUwNTQ5IzIxOTI4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-advances-separate-clinical-trials-evaluating-investigational-cd47-inhibitor-evorpacept-and-novel-egfr-targeted-antibody-drug-conjugate-alx2004\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925416","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=925416"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/925416\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=925416"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=925416"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=925416"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}